NCT02619097View on ClinicalTrials.gov

Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Myelodysplastic SyndromesAnemia
Interventions
DRUG

Pegol-sihematide injection

single dose

Trial Locations (1)

300020

RECRUITING

Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY